These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
410 related articles for article (PubMed ID: 35700773)
1. METTL3 Inhibits Antitumor Immunity by Targeting m Chen H; Pan Y; Zhou Q; Liang C; Wong CC; Zhou Y; Huang D; Liu W; Zhai J; Gou H; Su H; Zhang X; Xu H; Wang Y; Kang W; Kei Wu WK; Yu J Gastroenterology; 2022 Oct; 163(4):891-907. PubMed ID: 35700773 [TBL] [Abstract][Full Text] [Related]
2. RNA N Chen H; Gao S; Liu W; Wong CC; Wu J; Wu J; Liu D; Gou H; Kang W; Zhai J; Li C; Su H; Wang S; Soares F; Han J; He HH; Yu J Gastroenterology; 2021 Mar; 160(4):1284-1300.e16. PubMed ID: 33217448 [TBL] [Abstract][Full Text] [Related]
3. Targeting m Bao Y; Zhai J; Chen H; Wong CC; Liang C; Ding Y; Huang D; Gou H; Chen D; Pan Y; Kang W; To KF; Yu J Gut; 2023 Aug; 72(8):1497-1509. PubMed ID: 36717220 [TBL] [Abstract][Full Text] [Related]
4. Targeting ESE3/EHF With Nifurtimox Inhibits CXCR2 Xie Y; Zhou T; Li X; Zhao K; Bai W; Hou X; Liu Z; Ni B; Zhang Z; Yan J; Wang Y; Jiang W; Wang H; Chang A; Gao S; Zhao T; Yang S; Huang C; Liu J; Hao J Gastroenterology; 2024 Jul; 167(2):281-297. PubMed ID: 38492894 [TBL] [Abstract][Full Text] [Related]
5. m Wang L; Hui H; Agrawal K; Kang Y; Li N; Tang R; Yuan J; Rana TM EMBO J; 2020 Oct; 39(20):e104514. PubMed ID: 32964498 [TBL] [Abstract][Full Text] [Related]
6. ALKBH5 Drives Immune Suppression Via Targeting AXIN2 to Promote Colorectal Cancer and Is a Target for Boosting Immunotherapy. Zhai J; Chen H; Wong CC; Peng Y; Gou H; Zhang J; Pan Y; Chen D; Lin Y; Wang S; Kang W; To KF; Chen Z; Nie Y; He HH; Sung JJ; Yu J Gastroenterology; 2023 Aug; 165(2):445-462. PubMed ID: 37169182 [TBL] [Abstract][Full Text] [Related]
7. METTL3 facilitates tumor progression via an m Li T; Hu PS; Zuo Z; Lin JF; Li X; Wu QN; Chen ZH; Zeng ZL; Wang F; Zheng J; Chen D; Li B; Kang TB; Xie D; Lin D; Ju HQ; Xu RH Mol Cancer; 2019 Jun; 18(1):112. PubMed ID: 31230592 [TBL] [Abstract][Full Text] [Related]
8. The chemokine CXCL1 and its receptor CXCR2 contribute to chronic stress-induced depression in mice. Chai HH; Fu XC; Ma L; Sun HT; Chen GZ; Song MY; Chen WX; Chen YS; Tan MX; Guo YW; Li SP FASEB J; 2019 Aug; 33(8):8853-8864. PubMed ID: 31034777 [TBL] [Abstract][Full Text] [Related]
9. DCLK1 Suppresses Tumor-Specific Cytotoxic T Lymphocyte Function Through Recruitment of MDSCs via the CXCL1-CXCR2 Axis. Yan R; Li J; Xiao Z; Fan X; Liu H; Xu Y; Sun R; Liu J; Yao J; An G; Shi Y; Ge Y Cell Mol Gastroenterol Hepatol; 2023; 15(2):463-485. PubMed ID: 36309200 [TBL] [Abstract][Full Text] [Related]
10. m Shen C; Xuan B; Yan T; Ma Y; Xu P; Tian X; Zhang X; Cao Y; Ma D; Zhu X; Zhang Y; Fang JY; Chen H; Hong J Mol Cancer; 2020 Apr; 19(1):72. PubMed ID: 32245489 [TBL] [Abstract][Full Text] [Related]
12. Targeting of SLC25A22 boosts the immunotherapeutic response in KRAS-mutant colorectal cancer. Zhou Q; Peng Y; Ji F; Chen H; Kang W; Chan LS; Gou H; Lin Y; Huang P; Chen D; Wei Q; Su H; Liang C; Zhang X; Yu J; Wong CC Nat Commun; 2023 Aug; 14(1):4677. PubMed ID: 37542037 [TBL] [Abstract][Full Text] [Related]
13. SUMOylation of methyltransferase-like 3 facilitates colorectal cancer progression by promoting circ_0000677 in an m Liu Q; Huang Q; Liu H; He FJ; Liu JH; Zhou YY; Zeng MT; Pei Q; Zhu H J Gastroenterol Hepatol; 2022 Apr; 37(4):700-713. PubMed ID: 35030640 [TBL] [Abstract][Full Text] [Related]
14. CXCL8 Associated Dendritic Cell Activation Marker Expression and Recruitment as Indicators of Favorable Outcomes in Colorectal Cancer. Li E; Yang X; Du Y; Wang G; Chan DW; Wu D; Xu P; Ni P; Xu D; Hu Y Front Immunol; 2021; 12():667177. PubMed ID: 34025668 [TBL] [Abstract][Full Text] [Related]
15. Loss of SMAD4 Promotes Colorectal Cancer Progression by Recruiting Tumor-Associated Neutrophils via the CXCL1/8-CXCR2 Axis. Ogawa R; Yamamoto T; Hirai H; Hanada K; Kiyasu Y; Nishikawa G; Mizuno R; Inamoto S; Itatani Y; Sakai Y; Kawada K Clin Cancer Res; 2019 May; 25(9):2887-2899. PubMed ID: 30705034 [TBL] [Abstract][Full Text] [Related]
16. METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N Wan W; Ao X; Chen Q; Yu Y; Ao L; Xing W; Guo W; Wu X; Pu C; Hu X; Li Z; Yao M; Luo D; Xu X Mol Cancer; 2022 Feb; 21(1):60. PubMed ID: 35197058 [TBL] [Abstract][Full Text] [Related]
17. METTL3 promotes colorectal carcinoma progression by regulating the m6A-CRB3-Hippo axis. Pan J; Liu F; Xiao X; Xu R; Dai L; Zhu M; Xu H; Xu Y; Zhao A; Zhou W; Dang Y; Ji G J Exp Clin Cancer Res; 2022 Jan; 41(1):19. PubMed ID: 35012593 [TBL] [Abstract][Full Text] [Related]
18. Targeted Deletion of CXCR2 in Myeloid Cells Alters the Tumor Immune Environment to Improve Antitumor Immunity. Yang J; Yan C; Vilgelm AE; Chen SC; Ayers GD; Johnson CA; Richmond A Cancer Immunol Res; 2021 Feb; 9(2):200-213. PubMed ID: 33177110 [TBL] [Abstract][Full Text] [Related]
19. METTL3 promotes proliferation and migration of colorectal cancer cells by increasing SNHG1 stability. Xu Y; Bao Y; Qiu G; Ye H; He M; Wei X Mol Med Rep; 2023 Nov; 28(5):. PubMed ID: 37772373 [TBL] [Abstract][Full Text] [Related]
20. CXCR2 is essential for cerebral endothelial activation and leukocyte recruitment during neuroinflammation. Wu F; Zhao Y; Jiao T; Shi D; Zhu X; Zhang M; Shi M; Zhou H J Neuroinflammation; 2015 May; 12():98. PubMed ID: 25990934 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]